2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on CML: How Does Ponatinib Dose Reduction Affect Response in CP Disease?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Michael Deininger
By 2020 ASCO Virtual Direct™ Highlights FEATURING Michael Deininger
363 views
October 12, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

04:43
Treatment Approach for Advanced Ovarian Cancer

The Role Of Folate Receptor Alpha In Ovarian Cancer

Feat. D. M. O'Malley
Hematologic Oncology
08:07

2020 ASCO Update on R/R AML: Is AMG 330 Safe and Tolerable?

2020 ASCO Virtual Direct™ Highlights

M. Deininger

115 views
10:21

2020 ASCO Update on Newly Diagnosed AML: How Safe Is ENA+AZA Combina…

2020 ASCO Virtual Direct™ Highlights

M. Deininger

79 views
06:41

2020 ASCO Update on IDH1-Mutated AML: How Tolerated is IVO/VEN/AZA C…

2020 ASCO Virtual Direct™ Highlights

M. Deininger

60 views
09:47

2020 ASCO Update on CML: How Does Ponatinib Dose Reduction Affect Re…

2020 ASCO Virtual Direct™ Highlights

M. Deininger

363 views